Company news

Gain Therapeutics, Inc. news in 2024

Gain Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease

December 22, 2024

Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update

November 13, 2024

Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2

October 22, 2024

Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

October 14, 2024

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

October 6, 2024

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease

August 28, 2024

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

August 7, 2024

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease

July 8, 2024

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

June 26, 2024

Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

June 24, 2024

Gain Therapeutics Announces Pricing of $11.0 Million Public Offering

June 12, 2024

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024

May 29, 2024

Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update

May 13, 2024

Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

April 23, 2024

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

April 7, 2024

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

March 31, 2024

Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

March 25, 2024

Gain Therapeutics to Present at Public Ventures Discovery Day

March 14, 2024

Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease

March 4, 2024

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

February 26, 2024

Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight

February 13, 2024

Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

February 5, 2024

Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update

January 30, 2024

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024

January 1, 2024

Decks in 2024